Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + nab-paclitaxel followed by mFOLFIRINOX as first-line therapy for locally advanced or advanced pancreatic cancer
ChiCTR1900020538Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel, oxaliplatin, irinotecan, fluorouracil and 1 more in pancreatic cancer (PC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Jan 2019; status: recruiting.
02
Drugs
gemcitabinepaclitaxeloxaliplatinirinotecanfluorouracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR1900020538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020538.